Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$24k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
50.2% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
3.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
15
users have followed this narrative
7 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
1.4% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
52.2% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Cresco Labs
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Cannabis Markets Will Battle Price Compression While Gaining Cautious Relief
Key Takeaways Cresco Labs faces ongoing margin and revenue pressure from price compression, competition, and regulatory hurdles, despite operational efficiencies and expansion efforts. Growth is challenged by commoditization, evolving consumer demand, and risk of stagnant sales in saturated or uncertain regulatory markets.
View narrative
CA$1.50
FV
4.4% overvalued
intrinsic discount
0.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
OmniAb
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Regulatory Pressures And Competition Will Limit Prospects But Trigger Recovery
Key Takeaways Reliance on a limited partner base, rising regulatory pressures, and industry consolidation threaten revenue stability, platform adoption, and deal margins. Growing competition from alternative antibody discovery and AI-driven platforms may require higher R&D spending, risking long-term profitability and market share erosion.
View narrative
US$3.00
FV
33.0% undervalued
intrinsic discount
13.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Ceres Power Holdings
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Reduced Incentives And Global Rivals Will Restrict Hydrogen Prospects
Key Takeaways Reliance on government support and commercial partners adds significant risk to revenue stability and long-term profitability. Competitive pressures and uncertain technology economics could erode market share and make future growth assumptions overly optimistic.
View narrative
UK£0.90
FV
28.2% overvalued
intrinsic discount
2.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Gladstone Land
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Lease Shifts Will Squeeze Margins But Reveal Enduring Value
Key Takeaways Increasing exposure to volatile commodity prices and regulatory changes threatens earnings stability, margins, and long-term asset values. Reliance on specialty crops and external financing conditions heightens risks to revenue growth, tenant stability, and cash flow sustainability.
View narrative
US$9.00
FV
1.8% undervalued
intrinsic discount
4.29%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Xperi
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Open-source Adoption Will Erode Margins Though Limited Progress Will Continue
Key Takeaways Open-source and in-house technology adoption in media and automotive sectors threatens Xperi's proprietary software value, limiting future revenue growth and market opportunities. Increased industry consolidation and regulatory scrutiny may undermine Xperi's recurring revenue streams from middleware, advertising, and legacy patent licensing.
View narrative
US$9.00
FV
31.8% undervalued
intrinsic discount
-0.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Coveo Solutions
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Regulatory Pressures And Fierce Cloud Competition Will Erode Value
Key Takeaways Increasing regulatory hurdles and heightened competition from major cloud providers threaten Coveo's ability to differentiate and achieve sustainable revenue growth. Reliance on a few key partners and uncertain IT spending create risks for recurring revenue stability and margin protection.
View narrative
CA$7.97
FV
13.1% overvalued
intrinsic discount
14.93%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
3D Systems
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Margin Risks And Tariffs Will Dampen Healthcare But Yield Recovery
Key Takeaways Growth prospects in healthcare and critical markets are challenged by macroeconomic, trade, and adoption-related uncertainties among key customers. Innovation and restructuring efforts may be undermined by competition and execution risks, threatening profitability and long-term revenue stability.
View narrative
US$2.50
FV
16.4% undervalued
intrinsic discount
-4.49%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Alpha Teknova
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Funding Gaps Will Hamper Biopharma Yet Resilience Will Emerge
Key Takeaways Dependence on a limited product portfolio and slow new offerings may restrict growth amid challenges from industry consolidation and price competition. Margin improvements from process automation face risks from regulatory complexity, compliance costs, and supply chain shifts, threatening long-term profitability.
View narrative
US$8.00
FV
44.9% undervalued
intrinsic discount
14.20%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Verano Holdings
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Cannabis Competition And Credit Risk Will Erode Margins Yet Stabilize
Key Takeaways Regulatory shifts could expand markets but also intensify competition, leading to price pressure and margin challenges for Verano. Limited banking access and persistent regulatory burdens restrict capital, valuation growth, and sustainable long-term earnings despite operational and branding gains.
View narrative
CA$2.76
FV
29.3% undervalued
intrinsic discount
1.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies